22-1keynote 22JPM

OnCusp Therapeutics to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 27th, 2021 (Shanghai) — We are glad to announce that Andy Fu, the Co-Founder & CBO of OnCusp Therapeutics(昂阔医药), has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

Speech Topic: China to Global—License out strategy

演讲题目 :License-out: 中国企业面对MNC的谈判策略

About the speaker

Dr. Andy Fu has over 15 years of experience in healthcare, finance, management consulting, and biotech.

Before co-founding OnCusp, Dr. Fu was Vice President of Business Development and Corporate Strategy at CStone Pharmaceuticals. As a member of the founding management team, Dr. Fu played a critical role in designing CStone’s corporate strategy and leading the business development function. He closed eight partnerships in three years, including in-licensing, out-licensing, and multi-spectrum/equity deals.

Prior to CStone, he was at Monitor Deloitte China, where he specialized in Life Sciences strategy and M&A and helped to build the Healthcare M&A practice working with some of the largest Chinese healthcare companies.

Prior to Monitor Deloitte, Dr. Fu was deputy CEO at Yanlord Financial Services based in Sydney, Australia, where he co-led multiple M&A deals. Prior to Yanlord, Dr. Fu practiced as a pharmacist at Walgreens Pharmacy.

Dr. Fu holds both a Bachelor of Pharmacy and Doctor of Pharmacy from the University of Connecticut, and an MBA from INSEAD.


富天博士在医药及金融行业、管理咨询和商务扩展方面拥有超过十五年的从业经验。在创立昂阔医药之前,他曾在基石药业担任商务拓展及企业战略副总裁。做为基石创始团队的一员,在企业战略制定和商务拓展工作方面为公司做出了极为重要的贡献。在此期间,他成功达成了授权引进、对外许可和多方股权交易在内的八项重大合作。在加入基石药业之前,富天博士曾就职德勤公司,主要负责医疗行业的战略及兼并收购业务。他参与创建的医疗行业兼并收购业务团队曾服务多家中国医疗行业的龙头企业。在加入德勤之前,曾在位于澳大利亚悉尼的仁恒金融服务公司担任副首席执行官,并共同领导完成了多项兼并收购项目。此前,他曾在美国沃尔格林连锁药房(Walgreens Pharmacy)从事药剂师工作。



ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

If you are interested in listening to the live event, please register at https://biotochina.org/register/

Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang